criteria for starting glp 1 GLP-1 receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits Who Qualifies for Semaglutide GLP-1

JCI Insight 7 , e159863 (2022)

You should also speak to your doctor or other healthcare professionals, especially if you have any pre-existing health conditions, as they can help with dosing decisions and managing potential interactions with medications or supplements

These are not trivial improvements

Our results are in line with a recent network meta-analysis including 764 trials and 421,346 patients [25] which demonstrated that use of GLP-1RA reduces all cause and cardiovascular mortality, non-fatal myocardial infarction, non-fatal stroke, and kidney failure, with a substantial benefit on non-fatal stroke over SGLT-2 inhibitors and notable differences in the tolerability profile